DUBLIN, September 15, 2021--(BUSINESS WIRE)--The "Hyperuricemia (Metabolic Disorder) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.
Hyperuricemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 10, 6, 2, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.
Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)
Key Topics Covered:
Hyperuricemia - Overview
Hyperuricemia - Therapeutics Development
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperuricemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperuricemia - Companies Involved in Therapeutics Development
Allena Pharmaceuticals Inc
Arthrosi Therapeutics Inc
FortuneRock (China) Ltd
Fuji Yakuhin Co Ltd
Hangzhou Grand Biologic Pharmaceutical Inc
Hinova Pharmaceuticals Inc
J-Pharma Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Nippon Chemiphar Co Ltd
PegBio Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shanton Pharma Co Ltd
Stealth Biologics LLC
Suzhou Sinovent Pharmaceuticals Co Ltd
Teijin Pharma Ltd
Xiuzheng Pharmaceutical Group Co Ltd
Hyperuricemia - Drug Profiles
(allopurinol +verinurad) - Drug Profile
ABP-671 - Drug Profile
ALLN-346 - Drug Profile
allopurinol - Drug Profile
AR-882 - Drug Profile
D-0120 - Drug Profile
febuxostat - Drug Profile
HP-501 SR - Drug Profile
HZBio-1 - Drug Profile
JPH-367 - Drug Profile
JS-103 - Drug Profile
NC-2500 - Drug Profile
NC-2700 - Drug Profile
PB-348 - Drug Profile
Recombinant Enzyme for Gout and Hyperuricemia - Drug Profile
Recombinant Urate Oxidase Replacement for Acute Hyperuricemia - Drug Profile
SAP-001 - Drug Profile
SFR-9350 - Drug Profile
SHR-4640 - Drug Profile
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile
Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
taininade - Drug Profile
TMX-049 - Drug Profile
topiroxostat - Drug Profile
verinurad - Drug Profile
XNW-3009 - Drug Profile
YL-90148 - Drug Profile
Hyperuricemia - Dormant Projects
Hyperuricemia - Discontinued Products
Hyperuricemia - Product Development Milestones
Featured News & Press Releases
Jul 12, 2021: Allena Pharmaceuticals provides update on ALLN-346 clinical development program
Mar 05, 2021: Shanghai Junshi Bioscience announces JS103 Injection received the acceptance notice for the investigational new drug application
Nov 30, 2020: Allena Pharmaceuticals announces initial data from phase 1 trial of ALLN-346
Sep 08, 2020: Allena Pharmaceuticals doses first subject in phase 1 clinical trial of ALLN-346, in development for the treatment of Hyperuricemia in patients with gout and advanced chronic kidney disease
For more information about this report visit https://www.researchandmarkets.com/r/ycxhh3
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005775/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900